Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | Iptacopan for paroxysmal nocturnal hemoglobinuria

Regis Peffault de Latour • 2 Sep 2020
EBMT 2020
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Antibodies Eculizumab Iptacopan

Régis Peffault de Latour, MD, PhD, Saint-Louis Hospital, Paris, France, discusses the results of a study (NCT03439839) evaluating the safety and efficacy of iptacopan, a factor B inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) in combination with standard treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Regis Peffault de Latour

RACE: evaluating eltrombopag in severe aplastic anemia
2:55
RACE: evaluating eltrombopag in severe aplastic anemia
Regis Peffault de Latour • 3 Sep 2020
Overview of HSCT and GvHD at EBMT
1:17
Overview of HSCT and GvHD at EBMT
Regis Peffault de Latour • 3 Sep 2020
Eltrombopag for aplastic anaemia in Europe
2:01
Eltrombopag for aplastic anaemia in Europe
Regis Peffault de Latour • 1 Sep 2020
Aplastic anemia: EHA highlights
1:01
Aplastic anemia: EHA highlights
Regis Peffault de Latour • 15 Jun 2019

Related Videos

Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
3:10
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Regis Peffault de Latour • 8 Dec 2025
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
1:54
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
Regis Peffault de Latour • 2 Dec 2025
Exciting and potentially practice-changing hemophilia updates from ASH 2025
1:59
Exciting and potentially practice-changing hemophilia updates from ASH 2025
Regis Peffault de Latour • 12 Dec 2025
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
2:51
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
Regis Peffault de Latour • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals